N-(4-chlorophenyl)-3-methyl-3-phenylpiperidine-1-carboxamide | 1192067-50-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: N-(4-chlorophenyl)-3-methyl-3-phenylpiperidine-1-carboxamide
• CAS: 1192067-50-7
• 化学式: C₁₉H₂₁ClN₂O
• 分子量: 328.842
• InChiKey: KXYUVZFKXATOCP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  对氯苯异氰酸酯 、 3-甲基-3-苯基哌啶 以 二氯甲烷 为溶剂， 以80%的产率得到N-(4-chlorophenyl)-3-methyl-3-phenylpiperidine-1-carboxamide
  参考文献：
  名称：

  Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors

  摘要：

  3,3-Disubstituted piperidine-derived trisubstituted urea entA-2b was discovered as a highly potent and selective soluble epoxide hydrolase (sEH) inhibitor. Despite the good compound oral exposure, excellent sEH inhibition in whole blood, and remarkable selectivity, compound entA-2b failed to lower blood pressure acutely in spontaneously hypertensive rats (SHRs). This observation further challenges the premise that sEH inhibition can provide a viable approach to the treatment of hypertensive patients. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.07.138

文献信息

• Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors
  作者：Hong C. Shen、Fa-Xiang Ding、Qiaolin Deng、Suoyu Xu、Hsuan-shen Chen、Xinchun Tong、Vincent Tong、Xiaoping Zhang、Yuli Chen、Gaochao Zhou、Lee-Yuh Pai、Magdalena Alonso-Galicia、Bei Zhang、Sophie Roy、James R. Tata、Joel P. Berger、Steven L. Colletti

  DOI：10.1016/j.bmcl.2009.07.138

  日期：2009.9

  3,3-Disubstituted piperidine-derived trisubstituted urea entA-2b was discovered as a highly potent and selective soluble epoxide hydrolase (sEH) inhibitor. Despite the good compound oral exposure, excellent sEH inhibition in whole blood, and remarkable selectivity, compound entA-2b failed to lower blood pressure acutely in spontaneously hypertensive rats (SHRs). This observation further challenges the premise that sEH inhibition can provide a viable approach to the treatment of hypertensive patients. (C) 2009 Elsevier Ltd. All rights reserved.